Počet záznamov: 1
XIII. Výročný kongres Medzinárodnej spoločnosti pre farmakoekonomiku a výskum výsledkov. Toronto, 3.-7.V.2008
SYS 0036234 LBL 00000naa^^22^^^^^^^^450 005 20091111134834.9 100 $a 20091105a2008 m y0sloy0103 ba 101 0-
$a slo 102 $a SK 200 1-
$a <XIII.> Výročný kongres Medzinárodnej spoločnosti pre farmakoekonomiku a výskum výsledkov. Toronto, 3.-7.V.2008 $h Časť 2. $i Diabetológia, kardiológia, neurológia $f Lenka Petrová, Veronika Dubajová, Viliam Foltán 300 $a Voľný preklad z kongresových materiálov 327 0-
$a Cost-effectiveness of drug therapy for diabetes mellitus - a systematic review / Y. J. Zhang $a Cost and effectiveness of insulin vs rosiglitazone in type II diabetes after metformin monotherapy failure / J. Skoupá $a Comparison of resource utilization (RU) and cost in drug naive type 2 diabetes (T2D) patients treated with rosiglitazone (RSG) verzus sulfonylurea (SU) monotherapy / A. Gosselin $a Hagedorn in type 1 diabetes patients in the Czech setting - data from PREDICTIVE™ study / J. P. Clegg $a Cost-effectiveness of insulin detemir compared to NPH insulin for type 2 diabetes mellitus (T2DM) in the Canadian payer setting: modeling analysis using an observational study / M. E. Minshall $a Clinical and economic characteristics of patienta with diabetic neuropathy / Y. Zhao $a Medical care of patients with diabetic neuropathy: impact of type 1 diabetes and presence of other diabetes-related complications / Y. Zhao $a Cost-effectiveness of insulin detemir versus NPH insulin for type 1 diabetes patients treated with basal-bolus therapy in Portugal / C. Silva $a A modelled cost-effectiveness analysis of switching patients with poorly controlled type 2 diabetes to insulin detemir from oral antidiabetics or NPH in the Austrian setting; data from the PREDICTIVE study / L. Stechemesser $a Exenatide utilization and effectiveness in a health plan population / B. Schroeder $a Canadian cost utility analysis comparing exenatide versus insulin glargine in patients with type 2 diabetes / D. Coyle $a Lost productivity associated with type 1 and type 2 diabetes in a commercially insured population / E. Durden $a Systematic review of adherence, compliance and Quality of life in type 2 diabets patients / J. B. Kumar $a Comparison of healthcare utilization and cost in type 2 diabetes patients initiating analog and human insulins / J. Margolis $a Likelihood and cost of adverse events in atrial fibrillation are associated with choice of acute conversion therapy / M. Belz $a Economic evaluation of atosiban versus beta-mimetics in the treatment of preterm labour in Germany / J. Wex $a Evaluation of resistant hypertension in a usual-care setting / C. McAdam-Marx $a Blood pressure success zone longitudinal study of succes (BPSZ - BLISS): an observational, multicenter study of the impact of the BPSZ educational program on blood pressure control, perzistence, compliance and treatment satisfaction. Enrollment metrics and baseline cohort characteristics / K. A. Payne l $a A modified RxRisk-V comorbidity index predicts adherence with lipid lowering therapy (LLT) / S. R. Ghate $a Assessment and quantification of the benefit risk ratio of rosuvastatin and atorvastatin from a meta-analysis of head-to-head randomised controlled trials / J. Wlodarczyk $a The cost and effectiveness of adherence-improving interventions for lipid-lowering and antihypertensive drugs / R. H. Chapman $a The cost-utility of aliskiren in the treatment of mild to moderate hypertension. A Canadian healthcare system perspective / A. Lee $a A flexible tool to estimate medical care costs for study events in cardiovascular endpoints trials / D. Thompson $a The impact of targeted member education on choice of preferred statin therapy after a formulary change / E. Cox $a Begian budget impact analyses of aliskiren (Tekturna®/Rasilez®) in hypertension / P. Lecomte $a The cost-effectiveness of aliskiren as add on to losartan and optimal antihypertensive therapy in patients with type 2 diabetes, hypertension and nephropathy in the UK setting / J. L. Palmer $a Patient adherence to cholesterol treatment (PACT): Canadian physician and patient perspectives / B. Beamer $a Clinical determinants of satisfaction and health related quality of life in patients with cardiac disease and dyslipidemia / A. D. Raju $a Bosentan is a cost-effective treatment for UK patients with pulmonary arterial hypertension of WHO class III / M. Stevenson $a Clopidogrel is cost-effective compared with aspirin in UK patients with a myocardial infarction WHO subsequently suatain an ischaemic stroke or diagnosis of peripheral arterial disease / M. Stevenson $a Impact of adoption of new antihypertensive drugs on the healthcare utilization in hypertensive patients / A. Ganguli $a Impact of prescription copay on adherence to renin-angiotensin system agents in heart failure patients / Xiaolan Ye $a Physical and patient-reported outcomes in multiple sclerosis / S. Kirzinger $a Migraine suffers show significant health care utilization and expenditures / R. G. Iyer $a Modeling the impact of a fixed-dose combination of sumatriptan and naproxen sodium on triptan consumption in a US managed care population / T. W. Smith $a Severity of illness among persons with multiple sclerosis: an analysis of cost quintiles / N. L. Kleinman $a Prevalence and costs of comorbidities among persons with and without multiple sclerosis: an analysis of the AHRQ major and specific diagnostic categories / R. A. Brook $a Relationship between adherence to multiple sclerosis medications and total health care costs / N. G. Khandelwal $a Exploring the impact of different dispensing systems on medication compliance and persistence in multiple sclerosis patients using pharmacy claims data / J. Tang $a Cost of disability and medically-related absenteeism among employees with multiple sclerosis / H. G. Birnbaum $a Comparison of compliance and persistence with immunomodulating agents for multiple sclerosis in a commercially insured population / T. Shea $a Association between change in overall quality of life (QoL), disease level and functional status since natalizumab initiation / K. Rajagopalan $a Switching to high-dose, high-frequency interferons or natalizumab in patients with multiple sclerosis: a cost-effectiveness analysis / C. Fischer $a Medical costs associated with treatment change in multiple sclerosis / B. L. Nordstrom $a Impact of non-adherence to antiepileptic drugs on morbidity: results from a medicaid population / J. R. Weiner $a The concentration and persistence of health care expenditures and prescription drug expenditures in patients with Alzheimer's disease / Pei-Jung Lin 463 -1
$1 001 sllk_un_cat*0036030 $1 011 $a 1336-7021 $1 200 1 $a Farmakoekonomika a lieková politika $e oficiálny časopis Slovenskej spoločnosti pre farmakoekonomiku $v Roč. 4, č. 3 (2008), s. 27-28 a 30-53 $1 210 $a Nové Mesto nad Váhom $c TISING $d 2008 $1 215 $a s. 2-64 532 0-
$a Trinásty Výročný kongres Medzinárodnej spoločnosti pre farmakoekonomiku a výskum výsledkov. Toronto, 3.-7.V.2008 601 12
$3 sllk_un_auth*0012504 $a International Society for Pharmacoeconomics and Outcomes Research $b Annual international meeting $d 13. $e Toronto, Kanada $f 2008 606 1-
$3 sllk_un_auth*d017850 $a farmakoekonomika $2 mesh 606 1-
$3 sllk_un_auth*d003365 $a náklady a analýza nákladov $2 mesh 606 2-
$3 sllk_un_auth*d003920 $a diabetes mellitus $x ekonomika $2 mesh 606 2-
$3 sllk_un_auth*d048909 $a komplikácie diabetu $x ekonomika $2 mesh 606 2-
$3 sllk_un_auth*d002318 $a choroby kardiovaskulárne $x ekonomika $2 mesh 606 2-
$3 sllk_un_auth*d009422 $a choroby nervového systému $x ekonomika $2 mesh 606 2-
$3 sllk_un_auth*d004358 $a farmakoterapia $x ekonomika $2 mesh 700 -1
$3 sllk_un_auth*0012508 $a Petrová $b Lenka $p Slovenská spoločnosť pre farmakoekonomiku, Bratislava $4 070 701 -1
$3 sllk_un_auth*0002534 $a Dubajová $b Veronika $p Farmaceutická fakulta Univerzity Komenského, Bratislava $4 070 701 -1
$3 sllk_un_auth*p0006465 $a Foltán $b Viliam $f 1946- $p Katedra organizácie a riadenia farmácie, FaF UK, Bratislava $4 070 801 -0
$a SK $b BA006 $c 20091105 $g AACR2
Počet záznamov: 1